Gregory Covino - Biogen Chief Accounting Officer, Vice President - Finance
| BIIB Stock | MXN 3,410 112.89 3.20% |
President
Mr. Gregory F. Covino is no longer Chief Accounting Officer, Vice President Finance of Biogen Inc., effective July 11, 2018. He is also served as our interim Principal Financial Officer. From March 2010 to April 2012, Mr. Covino served at Boston Scientific Corporationrationration, a medical device company, as Vice President, Corporationrationrate Analysis and Control, having responsibility for the company internal audit function, and as Vice President, Finance, International from February 2008 to March 2010, having responsibility for the financial activities of the company international division. Prior to that, Mr. Covino held several finance positions at Hubbell Incorporated, an electrical products company, including Vice President, Chief Accounting Officer and Controller from 2002 to January 2008, Interim Chief Financial Officer from 2004 to 2005, and Director, Corporationrationrate Accounting from 1999 to 2002. since 2017.
| Age | 51 |
| Tenure | 7 years |
| Phone | 617 679 2000 |
| Web | https://www.biogen.com |
Biogen Management Efficiency
The company has return on total asset (ROA) of 0.076 % which means that it generated a profit of $0.076 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2023 %, meaning that it generated $0.2023 on every $100 dollars invested by stockholders. Biogen's management efficiency ratios could be used to measure how well Biogen manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Robert Kraft | CVS Health | 46 | |
| John Doig | The Bank of | N/A | |
| James Nickolas | Martin Marietta Materials | 52 | |
| Maria Theofilaktidis | The Bank of | N/A | |
| Laurie Stang | The Bank of | N/A | |
| Stephen Gold | CVS Health | 56 | |
| Marian Lawson | The Bank of | N/A | |
| John Mohr | Martin Marietta Materials | 58 | |
| Stan Alexander | Southwest Airlines | N/A | |
| Joseph Payne | Air Transport Services | 59 | |
| Jason Eaton | Southwest Airlines | N/A | |
| Rajagopal Viswanathan | The Bank of | N/A | |
| Anne Lloyd | Martin Marietta Materials | 53 | |
| Robert Jordan | Southwest Airlines | 62 | |
| Robin Hibberd | The Bank of | N/A | |
| William Payne | Air Transport Services | 53 | |
| Derica Rice | CVS Health | 53 | |
| Ian Arellano | The Bank of | N/A | |
| Terry Fryett | The Bank of | N/A | |
| Richard Corrado | Air Transport Services | 63 | |
| James Clark | CVS Health | 58 | |
Management Performance
| Return On Equity | 0.2 | |||
| Return On Asset | 0.076 |
Biogen Inc Leadership Team
Elected by the shareholders, the Biogen's board of directors comprises two types of representatives: Biogen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biogen. The board's role is to monitor Biogen's management team and ensure that shareholders' interests are well served. Biogen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biogen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher Viehbacher, CEO Pres | ||
| Robin Kramer, Chief Accounting Officer, Vice President | ||
| Jesus Mantas, Director | ||
| Richard Mulligan, Independent Director | ||
| Paul McKenzie, Executive Vice President - Pharmaceutical Operations & Technology | ||
| Michel Vounatsos, Vice President and Chief Commercial Officer | ||
| Sanjay Jariwala, Senior Vice President - Worldwide Medical | ||
| Susan Esq, Chief VP | ||
| George Scangos, CEO, Director | ||
| Alfred Sandrock, Executive Vice President - Neurology Discovery and Development and Chief Medical Officer | ||
| Spyros ArtavanisTsakonas, Senior Vice President Chief Scientific Officer | ||
| Alexander Denner, Independent Director | ||
| Natacha Gassenbach, Chief Affairs | ||
| JeanPaul Kress, Executive Vice President and Presidentident - International and Head of Global Therapeutic Operations | ||
| Eric Rowinsky, Independent Director | ||
| William Hawkins, Director | ||
| Adriana Karaboutis, Executive Vice President - Technology , Business Solutions and Corporate Affairs | ||
| Mark Hernon, Senior Vice President CIO | ||
| Kenneth Pietro, Executive Vice President - Human Resources | ||
| John Chiminski, Director | ||
| Adam Koppel, Executive Vice President - Strategy and Business Development | ||
| Stephen Sherwin, Independent Director | ||
| Caroline Dorsa, Independent Director | ||
| Michael Ehlers, Executive Vice President of Research and Development | ||
| Ginger Gregory, Chief Human Resource Officer, Executive Vice President | ||
| Chirfi Guindo, Executive Vice President Head of Global Marketing, Market Access and Customer Innovation | ||
| Susan Alexander, Executive Vice President Chief Legal Officer and Corporate Secretary | ||
| Catherine Steele, Senior Vice President - Corporate Affairs | ||
| Daniel Karp, Executive Vice President - Corporate Development | ||
| Paul Clancy, CFO, Executive Vice President - Finance | ||
| Steven Holtzman, Executive Vice President - Corporate Development | ||
| Anirvan Ghosh, Senior Vice President - Research and Early Development | ||
| Michael CPA, Ex CFO | ||
| Nancy Leaming, Independent Director | ||
| Nicole Murphy, Head Technology | ||
| Michael Hencke, Head Relations | ||
| Lynn Schenk, Independent Director | ||
| Camille Lee, Senior Vice President - Alzheimer's Therapeutic Area | ||
| Brian Posner, Independent Director | ||
| Gregory Covino, Chief Accounting Officer, Vice President - Finance | ||
| Anabella Villalobos, Senior Vice President - Biotherapeutic & Medicinal Sciences (BTMS) | ||
| Stelios Papadopoulos, Independent Chairman of the Board | ||
| John Cox, Executive Vice President - Global Commercial Operations | ||
| Robert Pangia, Independent Director | ||
| Jeffrey Capello, CFO, Executive Vice President |
Biogen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biogen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.2 | |||
| Return On Asset | 0.076 | |||
| Profit Margin | 0.28 % | |||
| Operating Margin | 0.29 % | |||
| Current Valuation | 861.61 B | |||
| Shares Outstanding | 144 M | |||
| Shares Owned By Insiders | 0.68 % | |||
| Shares Owned By Institutions | 89.99 % | |||
| Price To Earning | 169.05 X | |||
| Price To Book | 3.30 X |
Pair Trading with Biogen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biogen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biogen will appreciate offsetting losses from the drop in the long position's value.Moving together with Biogen Stock
| 0.94 | ROGN | Roche Holding AG | PairCorr |
| 0.68 | AMGN | Amgen Inc | PairCorr |
Moving against Biogen Stock
| 0.94 | AXTELCPO | Axtel SAB de Earnings Call This Week | PairCorr |
| 0.72 | LLY | Eli Lilly | PairCorr |
| 0.48 | CEMEXCPO | CEMEX SAB de Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Biogen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biogen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biogen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biogen Inc to buy it.
The correlation of Biogen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biogen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biogen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biogen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biogen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Complementary Tools for Biogen Stock analysis
When running Biogen's price analysis, check to measure Biogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biogen is operating at the current time. Most of Biogen's value examination focuses on studying past and present price action to predict the probability of Biogen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biogen's price. Additionally, you may evaluate how the addition of Biogen to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |